Akouos Inc. (AKUS) News

Akouos Inc. (AKUS): $3.30

-0.16 (-4.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter AKUS News Items

AKUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AKUS News Highlights

  • For AKUS, its 30 day story count is now at 4.
  • Over the past 10 days, the trend for AKUS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • GENE, CMC and STAR are the most mentioned tickers in articles about AKUS.

Latest AKUS News From Around the Web

Below are the latest news stories about Akouos Inc that investors may wish to consider to help them evaluate AKUS as an investment opportunity.

BTIG Thinks AKOUOS’s Stock is Going to Recover

BTIG analyst Robert Hazlett reiterated a Buy rating on AKOUOS (AKUS – Research Report) yesterday and set a price target of $35.00. The company's shares closed last Wednesday at $6.02, close to its 52-week low of $5.30. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.1% and a 32.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Syndax Pharmaceuticals, and TRACON Pharmaceuticals. AKOUOS has an analyst consensus of Moderate Buy, with a price target consensus of $30.00, representing a 419.0% upside. In a report issued on February 7, H.C.

Howard Kim on TipRanks | February 10, 2022

H.C. Wainwright Reaffirms Their Buy Rating on AKOUOS (AKUS)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on AKOUOS (AKUS – Research Report) today and set a price target of $25.00. The company's shares closed last Monday at $5.81, close to its 52-week low of $5.30. According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.6% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AKOUOS with a $25.00 average price target.

Howard Kim on TipRanks | February 7, 2022

Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive widespread GJB2 expression in supporting cells, while limiting expression in, and loss of, hair cells in mice - AAV-mediated RNAi gene silencing and CRISPR/Cas9 gene editing methods demonstrate a promising reduction of gene of interest protein expression, which

Yahoo | February 7, 2022

Akouos to Participate in Upcoming February Virtual Investor Conferences

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February: Cowen 2nd Annual Genetic Medicines Summit. Panel discussion including Stacy Price, M.S., chief technical officer, titled “Hot Topics in CMC/Man

Yahoo | January 31, 2022

Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022. The two podium presentations and one poster will highlight no

Yahoo | January 7, 2022

We're Hopeful That Akouos (NASDAQ:AKUS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 20, 2021

Head-To-Head Contrast: Akouos (NASDAQ:AKUS) versus Ocular Therapeutix (NASDAQ:OCUL)

Akouos (NASDAQ:AKUS) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Akouos and Ocular Therapeutix, []

Dakota Financial News | November 26, 2021

Head to Head Comparison: DiaMedica Therapeutics (NASDAQ:DMAC) and Akouos (NASDAQ:AKUS)

DiaMedica Therapeutics (NASDAQ:DMAC) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends. Earnings & Valuation This table compares DiaMedica Therapeutics and Akouos top-line revenue, earnings per share and []

Dakota Financial News | November 24, 2021

Head to Head Survey: DiaMedica Therapeutics (NASDAQ:DMAC) versus Akouos (NASDAQ:AKUS)

DiaMedica Therapeutics (NASDAQ:DMAC) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings. Insider & Institutional Ownership 54.7% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 95.2% []

Transcript Daily | November 22, 2021

Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 33 rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

Intrado Digital Media | November 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5197 seconds.